CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody
Human CD200R1 (hCD200R1), an immune inhibitory receptor expressed predominantly on T cells and myeloid cells, was identified as a promising immuno-oncology target by the 23andMe database. Blockade of CD200R1-dependent signaling enhances T cell-mediated antitumor activity in vitro and in vivo. 23ME–0...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2410316 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576574333911040 |
|---|---|
| author | Cristina Melero S. Jimmy Budiardjo Anahita Daruwalla Lance Larrabee Oleg Ganichkin Alexander J. Heiler Jill Fenaux Ben Chung Germaine Fuh Yao-Ming Huang |
| author_facet | Cristina Melero S. Jimmy Budiardjo Anahita Daruwalla Lance Larrabee Oleg Ganichkin Alexander J. Heiler Jill Fenaux Ben Chung Germaine Fuh Yao-Ming Huang |
| author_sort | Cristina Melero |
| collection | DOAJ |
| description | Human CD200R1 (hCD200R1), an immune inhibitory receptor expressed predominantly on T cells and myeloid cells, was identified as a promising immuno-oncology target by the 23andMe database. Blockade of CD200R1-dependent signaling enhances T cell-mediated antitumor activity in vitro and in vivo. 23ME–00610 is a potential first-in-class, humanized IgG1 investigational antibody that binds hCD200R1 with high affinity. We have previously shown that 23ME–00610 inhibits the hCD200R1 immune checkpoint function. Herein, we dissect the molecular mechanism of 23ME–00610 blockade of hCD200R1 by solving the crystal structure of 23ME–00610 Fab in complex with hCD200R1 and performing mutational studies, which show 23ME–00610 blocks the interaction between hCD200 and hCD200R1 through steric hindrance. However, 23ME–00610 does not bind CD200R1 of preclinical species such as cynomolgus monkey MfCD200R1. To enable preclinical toxicology studies of CD200R1 blockade in a pharmacologically relevant non-clinical species, we engineered a surrogate antibody with high affinity toward MfCD200R1. We used phage display libraries of 23ME–00610 variants with individual CDR residues randomized to all 20 amino acids, from which we identified mutations that switched on MfCD200R1 binding. Structural analysis suggests how the surrogate, named 23ME–00611, acquires the ortholog binding ability at the equivalent epitope of 23ME–00610. This engineering approach does not require a priori knowledge of structural and functional mapping of antibody–antigen interaction and thus is generally applicable for therapeutic antibody development when desired ortholog binding is lacking. These findings provide foundational insights as 23ME–00610 advances in clinical studies to gain understanding of the hCD200R1 immune checkpoint as a target in immuno-oncology. |
| format | Article |
| id | doaj-art-c523efc8d50249edacd1a4181307eaa0 |
| institution | Kabale University |
| issn | 1942-0862 1942-0870 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | mAbs |
| spelling | doaj-art-c523efc8d50249edacd1a4181307eaa02025-01-31T04:19:38ZengTaylor & Francis GroupmAbs1942-08621942-08702024-12-0116110.1080/19420862.2024.2410316CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibodyCristina Melero0S. Jimmy Budiardjo1Anahita Daruwalla2Lance Larrabee3Oleg Ganichkin4Alexander J. Heiler5Jill Fenaux6Ben Chung7Germaine Fuh8Yao-Ming Huang923andMe, Therapeutic Unit, South San Francisco, CA, USA23andMe, Therapeutic Unit, South San Francisco, CA, USA23andMe, Therapeutic Unit, South San Francisco, CA, USA23andMe, Therapeutic Unit, South San Francisco, CA, USAProteros Biostructures, GmbH, Planegg Martinsried, Germany23andMe, Therapeutic Unit, South San Francisco, CA, USA23andMe, Therapeutic Unit, South San Francisco, CA, USA23andMe, Therapeutic Unit, South San Francisco, CA, USA23andMe, Therapeutic Unit, South San Francisco, CA, USA23andMe, Therapeutic Unit, South San Francisco, CA, USAHuman CD200R1 (hCD200R1), an immune inhibitory receptor expressed predominantly on T cells and myeloid cells, was identified as a promising immuno-oncology target by the 23andMe database. Blockade of CD200R1-dependent signaling enhances T cell-mediated antitumor activity in vitro and in vivo. 23ME–00610 is a potential first-in-class, humanized IgG1 investigational antibody that binds hCD200R1 with high affinity. We have previously shown that 23ME–00610 inhibits the hCD200R1 immune checkpoint function. Herein, we dissect the molecular mechanism of 23ME–00610 blockade of hCD200R1 by solving the crystal structure of 23ME–00610 Fab in complex with hCD200R1 and performing mutational studies, which show 23ME–00610 blocks the interaction between hCD200 and hCD200R1 through steric hindrance. However, 23ME–00610 does not bind CD200R1 of preclinical species such as cynomolgus monkey MfCD200R1. To enable preclinical toxicology studies of CD200R1 blockade in a pharmacologically relevant non-clinical species, we engineered a surrogate antibody with high affinity toward MfCD200R1. We used phage display libraries of 23ME–00610 variants with individual CDR residues randomized to all 20 amino acids, from which we identified mutations that switched on MfCD200R1 binding. Structural analysis suggests how the surrogate, named 23ME–00611, acquires the ortholog binding ability at the equivalent epitope of 23ME–00610. This engineering approach does not require a priori knowledge of structural and functional mapping of antibody–antigen interaction and thus is generally applicable for therapeutic antibody development when desired ortholog binding is lacking. These findings provide foundational insights as 23ME–00610 advances in clinical studies to gain understanding of the hCD200R1 immune checkpoint as a target in immuno-oncology.https://www.tandfonline.com/doi/10.1080/19420862.2024.241031623ME-00610cancer immunotherapyCD200CD200R1deep mutational scanimmune checkpoint |
| spellingShingle | Cristina Melero S. Jimmy Budiardjo Anahita Daruwalla Lance Larrabee Oleg Ganichkin Alexander J. Heiler Jill Fenaux Ben Chung Germaine Fuh Yao-Ming Huang CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody mAbs 23ME-00610 cancer immunotherapy CD200 CD200R1 deep mutational scan immune checkpoint |
| title | CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody |
| title_full | CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody |
| title_fullStr | CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody |
| title_full_unstemmed | CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody |
| title_short | CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody |
| title_sort | cd200r1 immune checkpoint blockade by the first in human anti cd200r1 antibody 23me 00610 molecular mechanism and engineering of a surrogate antibody |
| topic | 23ME-00610 cancer immunotherapy CD200 CD200R1 deep mutational scan immune checkpoint |
| url | https://www.tandfonline.com/doi/10.1080/19420862.2024.2410316 |
| work_keys_str_mv | AT cristinamelero cd200r1immunecheckpointblockadebythefirstinhumananticd200r1antibody23me00610molecularmechanismandengineeringofasurrogateantibody AT sjimmybudiardjo cd200r1immunecheckpointblockadebythefirstinhumananticd200r1antibody23me00610molecularmechanismandengineeringofasurrogateantibody AT anahitadaruwalla cd200r1immunecheckpointblockadebythefirstinhumananticd200r1antibody23me00610molecularmechanismandengineeringofasurrogateantibody AT lancelarrabee cd200r1immunecheckpointblockadebythefirstinhumananticd200r1antibody23me00610molecularmechanismandengineeringofasurrogateantibody AT olegganichkin cd200r1immunecheckpointblockadebythefirstinhumananticd200r1antibody23me00610molecularmechanismandengineeringofasurrogateantibody AT alexanderjheiler cd200r1immunecheckpointblockadebythefirstinhumananticd200r1antibody23me00610molecularmechanismandengineeringofasurrogateantibody AT jillfenaux cd200r1immunecheckpointblockadebythefirstinhumananticd200r1antibody23me00610molecularmechanismandengineeringofasurrogateantibody AT benchung cd200r1immunecheckpointblockadebythefirstinhumananticd200r1antibody23me00610molecularmechanismandengineeringofasurrogateantibody AT germainefuh cd200r1immunecheckpointblockadebythefirstinhumananticd200r1antibody23me00610molecularmechanismandengineeringofasurrogateantibody AT yaominghuang cd200r1immunecheckpointblockadebythefirstinhumananticd200r1antibody23me00610molecularmechanismandengineeringofasurrogateantibody |